Low-glucose conditions of tumor microenvironment enhance cytotoxicity of tetrathiomolybdate to neuroblastoma cells

Nutrition and Cancer

Volumn 65, Issue 5, 2013, Pages 702-710

  Navrátilová, Jarmila ^a   Hankeová, Tereza ^a   Beneš, Petr ^a,b   Šmarda, Jan ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; GLUCOSE; LACTIC ACID; PROTEIN KINASE B; TETRATHIOMOLYBDIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; NEUROBLASTOMA; NEUROBLASTOMA CELL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

AMP-ACTIVATED PROTEIN KINASES; ANGIOGENESIS INHIBITORS; ANOXIA; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GLUCOSE; HUMANS; MOLYBDENUM; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84880399893     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.789118     Document Type: Article

References (67)

1. Goodman VL, Brewer GJ, and Merajver SD: Control of copper status for cancer therapy. Curr Cancer Drug Targets 5, 543-549, 2005.
2. Yoshii J, Yoshiji H, Kuriyama S, Ikenaka Y, Noguchi R, et al.: The copperchelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer 94, 768-773, 2001.
3. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, et al.: Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62, 4854-4859, 2002.
4. Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, et al.: The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 111, 696-701, 2001.
5. Kumar P, Yadav A, Patel SN, Islam M, Pan Q, et al.: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer 9, 206, 2010.
6. Tisato F, Marzano C, Porchia M, Pellei M, and Santini C: Copper in diseases and treatments, and copper-based anticancer strategies. Med Res Rev 30, 708-749, 2010.
7. Goodman VL, Brewer GJ, and Merajver SD: Copper deficiency as an anticancer strategy. Endocr Relat Cancer 11, 255-263, 2004.
8. Brem SS, Zagzag D, Tsanaclis AM,Gately S, Elkouby MP, et al.: Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 137, 1121-1142, 1990.
9. Brem S, Tsanaclis AM, and Zagzag D: Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery 26, 391-396, 1990.
10. Brem S, Grossman SA, Carson KA, New P, Phuphanich S, et al.: Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol 7, 246-253, 2005.
11. Brem S: Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 6, 436-458, 1999.
12. Lombardo MF, Ciriolo MR, Rotilio G, and Rossi L: Prolonged copper depletion induces expression of antioxidants and triggers apoptosis in SHSY5Y neuroblastoma cells. Cell Mol Life Sci 60, 1733-1743, 2003.
13. Rossi L, Marchese E, Lombardo MF, Rotilio G, and Ciriolo MR: Increased susceptibility of copper-deficient neuroblastoma cells to oxidative stressmediated apoptosis. Free Radic Biol Med 30, 1177-1187, 2001.
14. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, et al.: Treatment ofWilson's diseasewith ammonium tetrathiomolybdate: I. Initial therapy in 17 neurologically affected patients. Arch Neurol 51, 545-554, 1994.
15. Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, et al.: Treatment of Wilson disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 53, 1017-1025, 1996.
16. Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, et al.: Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60, 379-385, 2003.
17. Ogra Y: Research tools and techniques for coppermetabolism in mammals. Journal of Health Science 57, 385-396, 2011.
18. Tokuda E, Ono S, Ishige K, Watanabe S, Okawa E, et al.: Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol 213, 122-128, 2008.
19. Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, et al.: Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63, 521-527, 2006.
20. Gooneratne SR, Laarveld B, Chaplin RK, and Christensen DA: Profiles of 67Cu in blood, bile, urine and faeces from 67Cu-primed lambs: effect of 99Mo-labelled tetrathiomolybdate on the metabolism of 67Cu after longterm storage. Br J Nutr 61, 373-385, 1989.
21. Brewer GJ,Dick RD,Yuzbasiyan-Gurkin V, TankanowR,Young AB, et al.: Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48, 42-47, 1991.
22. Brewer GJ: Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood) 226, 665-673, 2001.
23. Pass HI, Brewer GJ, Dick R, Carbone M, and Merajver S: A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 86, 383-390, 2008.
24. Khan G and Merajver S: Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. Expert Opin Investig Drugs 18, 541-548, 2009.
25. Warburg O: On the origin of cancer cells. Science 123, 309-314, 1956.
26. Guppy M, Greiner E, and Brand K: The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem 212, 95-99, 1993.
27. Cairns R, Papandreou I, and Denko N: Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4, 61-70, 2006.
28. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, et al.:Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 69, 4918-4925, 2009.
29. Diaz-Ruiz R, Rigoulet M, and Devin A: The Warburg and Crabtree effects: on the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim Biophys Acta 1807, 568-576, 2011.
30. Ibsen KH: The Crabtree effect: a review. Cancer Res 21, 829-841, 1961.
31. Jin S, DiPaola RS, Mathew R, and White E: Metabolic catastrophe as a means to cancer cell death. J Cell Sci 120, 379-383, 2007.
32. Skinner R, Trujillo A, Ma X, and Beierle EA: Ketone bodies inhibit the viability of human neuroblastoma cells. J Pediatr Surg 44, 212-216; discussion, 216, 2009.
33. Seyfried BT, Kiebish M, Marsh J, and Mukherjee P: Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet. J Cancer Res Ther 5, 7-15, 2009.
34. Tomida A, Yun J, and Tsuruo T: Glucose-regulated stresses induce resistance to camptothecin in human cancer cells. Int J Cancer 68, 391-396, 1996.
35. Shen J, Hughes C, Chao C, Cai J, Bartels C, et al.: Coinduction of glucoseregulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci USA 84, 3278-3282, 1987.
36. Hwang JH, Kim JY, Cha MR, Ryoo IJ, Choo SJ, et al.: Etoposide-resistant HT-29 human colon carcinoma cells during glucose deprivation are sensitive to piericidin A, a GRP78 down-regulator. J Cell Physiol 215, 243-250, 2008.
37. Hughes CS, Shen JW, and Subjeck JR: Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res 49, 4452-4454, 1989.
38. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, et al.: Starvationdependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci USA 105, 8215-8220, 2008.
39. Jungova P, Navratilova J, Pes O, Vaculovic T, Kanicky V, et al.: Substrateassisted laser desorption inductively-coupled plasma mass spectrometry for determination of copper in myeloid leukemia cells. Journal of Analytical Atomic Spectrometry 25, 662-668, 2010.
40. Navratilova J, Jungova P, Vanhara P, Preisler J, Kanicky V, et al.: Copper ions regulate cytotoxicity of disulfiram to myeloid leukemia cells. Int J Mol Med 24, 661-670, 2009.
41. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, et al.: Aktdirected glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 23, 7315-7328, 2003.
42. Steinberg GR and Kemp BE: AMPK in health and disease. Physiol Rev 89, 1025-1078, 2009.
43. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, et al.: Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 175, 913-923, 2006.
44. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, et al.: Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2, 21-33, 2005.
45. Gybina AA and Prohaska JR: Variable response of selected cuproproteins in rat choroid plexus and cerebellum following perinatal copper deficiency. Genes Nutr 1, 51-59, 2006.
46. Li Y, Park JS, Deng JH, and Bai Y: Cytochrome c oxidase subunit IV is essential for assembly and respiratory function of the enzyme complex. J Bioenerg Biomembr 38, 283-291, 2006.
47. Momose I, Ohba S, Tatsuda D, Kawada M, Masuda T, et al.:Mitochondrial inhibitors showpreferential cytotoxicity to human pancreatic cancer PANC- 1 cells under glucose-deprived conditions. Biochem Biophys Res Commun 392, 460-466, 2010.
48. Vaupel P, Kallinowski F, and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49, 6449-6465, 1989.
49. Brown JM and Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416, 1998.
50. Pan Q, Bao LW, and Merajver SD: Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 1, 701-706, 2003.
51. Gybina AA and Prohaska JR: Augmented cerebellar lactate in copper deficient rat pups originates from both blood and cerebellum. Metab Brain Dis 24, 299-310, 2009.
52. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, et al.: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64, 3892-3899, 2004.
53. Coloff JL, Mason EF, Altman BJ, Gerriets VA, Liu T, et al.: Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem 286, 5921-5933, 2011.
54. Gybina AA and Prohaska JR: Copper deficiency results in AMP-activated protein kinase activation and acetylCoA carboxylase phosphorylation in rat cerebellum. Brain Res 1204, 69-76, 2008.
55. Carling D: The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 29, 18-24, 2004.
56. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, et al.: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 6, 1-10, 2000.
57. Linder MC, Houle PA, Isaacs E, Moor JR, and Scott LE: Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme 24, 23-35, 1979.
58. Zeng H, Saari JT, and Johnson WT: Copper deficiency decreases complex IV but not complex I, II, III, or V in the mitochondrial respiratory chain in rat heart. J Nutr 137, 14-18, 2007.
59. Shoubridge EA: Cytochrome c oxidase deficiency. Am J Med Genet 106, 46-52, 2001.
60. Hardie DG: Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 93, 891S-896, 2011.
61. Garland JM and Halestrap A: Energy metabolism during apoptosis. Bcl-2 promotes survival in hematopoietic cells induced to apoptose by growth factor withdrawal by stabilizing a form of metabolic arrest. J Biol Chem 272, 4680-4688, 1997.
62. Vander Heiden MG, Chandel NS, Schumacker PT, and Thompson CB: BclxL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Mol Cell 3, 159-167, 1999.
63. Nakamura N and Wada Y: Properties of DNA fragmentation activity generated by ATP depletion. Cell Death Differ 7, 477-484, 2000.
64. Chernyak BV, Pletjushkina OY, Izyumov DS, Lyamzaev KG, and Avetisyan AV: Bioenergetics and death. Biochemistry (Mosc) 70, 240-245, 2005.
65. Huber HJ, Dussmann H, Kilbride SM, Rehm M, and Prehn JH: Glucose metabolism determines resistance of cancer cells to bioenergetic crisis after cytochrome-c release.Mol Syst Biol 7, 470, 2011.
66. Hochachka PW, Buck LT, Doll CJ, and Land SC: Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 93, 9493-9498, 1996.
67. Tredan O, Galmarini CM, Patel K, and Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99, 1441-1454, 2007.